{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:56:31Z","timestamp":1790686591817,"version":"4.1.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40272-026-00761-6","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:10:47Z","timestamp":1784801447000},"page":"465-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incorporating Immunotherapies into the Evolving Standard of Care for Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"28","author":[{"given":"Andrej","family":"Lissat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Brivio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Stutterheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friso","family":"Calkoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-8862","authenticated-orcid":false,"given":"Francisco","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"761_CR1","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(22)00637-4","volume":"23","author":"L Botta","year":"2022","unstructured":"Botta L, Gatta G, Capocaccia R, et al. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study. Lancet Oncol. 2022;23:1525\u201336.","journal-title":"Lancet Oncol"},{"key":"761_CR2","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1200\/JCO.23.01286","volume":"41","author":"R Pieters","year":"2023","unstructured":"Pieters R, Mullighan CG, Hunger SP. Advancing diagnostics and therapy to reach universal cure in childhood ALL. J Clin Oncol. 2023;41:5579\u201391.","journal-title":"J Clin Oncol"},{"key":"761_CR3","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1200\/JCO.23.02238","volume":"42","author":"T-C Chang","year":"2024","unstructured":"Chang T-C, Chen W, Qu C, et al. uGenomic determinants of outcome in acute lymphoblastic leukemia. J Clin Oncol. 2024;42:3491\u2013503.","journal-title":"J Clin Oncol"},{"key":"761_CR4","doi-asserted-by":"crossref","unstructured":"Andr\u00e9s-Jensen L, Nielsen CG, van den Heuvel-Eibrink MM, et al. Acute toxicity and late effects related to acute lymphoblastic leukemia treatment, in 2024, pp 279\u2013303.","DOI":"10.1007\/978-3-031-71180-0_18"},{"key":"761_CR5","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A Von Stackelberg","year":"2016","unstructured":"Von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381\u20139.","journal-title":"J Clin Oncol"},{"key":"761_CR6","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","volume":"36","author":"E Pennesi","year":"2022","unstructured":"Pennesi E, Michels N, Brivio E, et al. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results from a phase II trial. Leukemia. 2022;36:1516\u201324.","journal-title":"Leukemia"},{"key":"761_CR7","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/S1470-2045(24)00736-8","volume":"26","author":"ADJ Pearson","year":"2025","unstructured":"Pearson ADJ, Rossig C, Mackall CL, et al. New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis. Lancet Oncol. 2025;26:e214\u201324.","journal-title":"Lancet Oncol"},{"key":"761_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","volume":"392","author":"S Gupta","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA, et al. Blinatumomab in standard-risk b-cell acute lymphoblastic leukemia in children. N Engl J Med. 2025;392:875\u201391.","journal-title":"N Engl J Med"},{"key":"761_CR9","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM van der Sluis","year":"2023","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023;388:1572\u201381.","journal-title":"N Engl J Med"},{"key":"761_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41375-025-02800-6","volume":"40","author":"F Locatelli","year":"2026","unstructured":"Locatelli F, Rizzari C, Gruhn B, et al. Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study. Leukemia. 2026;40:230\u20134.","journal-title":"Leukemia"},{"key":"761_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab versus chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia. JAMA. 2021;325:833.","journal-title":"JAMA"},{"key":"761_CR12","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10:e433\u201344.","journal-title":"Lancet Haematol"},{"key":"761_CR13","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1200\/JCO-25-00307","volume":"43","author":"MJ Wieduwilt","year":"2025","unstructured":"Wieduwilt MJ, Yin J, Kour O, et al. Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed B-cell ALL: Alliance Study A041703 Cohort 1 results. J Clin Oncol. 2025;43:3526\u201335.","journal-title":"J Clin Oncol"},{"key":"761_CR14","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.1200\/JCO.2023.41.16_suppl.10016","volume":"41","author":"MM O\u2019Brien","year":"2023","unstructured":"O\u2019Brien MM, McNeer JL, Rheingold SR, et al. A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: second safety phase results from Children\u2019s Oncology Group AALL1732. J Clin Oncol. 2023;41:10016\u201310016.","journal-title":"J Clin Oncol"},{"key":"761_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-Cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843\u201354.","journal-title":"JAMA"},{"key":"761_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1200\/JCO-25-01806","volume":"44","author":"M Vieira Martins","year":"2026","unstructured":"Vieira Martins M, de Lorenzo P, Kotecha RS, et al. Sustained benefit of blinatumomab in infants with KMT2A-rearranged ALL: long-term outcomes, toxicity, and pharmacokinetics. J Clin Oncol. 2026;44:370\u20134.","journal-title":"J Clin Oncol"},{"key":"761_CR17","unstructured":"Blinatumomab for first line treatment in intermediate and high risk...\u2014Samarasinghe S\u2014Jun 13 2024. [cited 2026 Feb 15]. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422215\/sujith.samarasinghe.blinatumomab.for.first.line.treatment.in.intermediate.and.html."},{"key":"761_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1182\/blood-2025-547","volume":"146","author":"A Li","year":"2025","unstructured":"Li A, Kairalla J, Wang C, et al. Outcomes in children and adolescents with Down syndrome and B-lymphoblastic leukemia: a report from Children\u2019s Oncology Group study AALL1731. Blood. 2025;146:547\u2013547. https:\/\/doi.org\/10.1182\/blood-2025-547.","journal-title":"Blood"},{"key":"761_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2991\/chi.d.190219.001","volume":"1","author":"E Jacoby","year":"2019","unstructured":"Jacoby E. Relapse and resistance to CAR-T cells and blinatumomab in hematologic malignancies. Clin Hematol Int. 2019;1:79.","journal-title":"Clin Hematol Int"},{"key":"761_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318. https:\/\/doi.org\/10.1182\/blood.2022015956.","journal-title":"Blood"},{"key":"761_CR21","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell J, Dittrich M, Bedke T, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31:2181\u201390.","journal-title":"Leukemia"},{"key":"761_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71159","volume":"14","author":"W Yan","year":"2025","unstructured":"Yan W, Hu S, Gao W, et al. Leukemia burden impacts the efficacy and toxicity of blinatumomab in pediatric B-cell acute lymphoblastic leukemia. Cancer Med. 2025;14:e71159. https:\/\/doi.org\/10.1002\/cam4.71159.","journal-title":"Cancer Med"},{"key":"761_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"F Braig","year":"2017","unstructured":"Braig F, Brandt A, Goebeler M, et al. Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129:100\u20134.","journal-title":"Blood"},{"key":"761_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood.2020006287","volume":"137","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Aldoss I, Qu C, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137:471\u201384.","journal-title":"Blood"},{"key":"761_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1182\/blood.2024024517","volume":"145","author":"AJ Lamble","year":"2025","unstructured":"Lamble AJ, Kovach AE, Shah NN. How I treat postimmunotherapy relapsed B-ALL. Blood. 2025;145:64\u201374. https:\/\/doi.org\/10.1182\/blood.2024024517.","journal-title":"Blood"},{"key":"761_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2024-208674","volume":"144","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, Li J, Zhang J, et al. TP53 mutations increased the risk of CD19 negative relapse following blinatumomab in adults with B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2024;144:729\u2013729. https:\/\/doi.org\/10.1182\/blood-2024-208674.","journal-title":"Blood"},{"key":"761_CR27","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1080\/10428194.2023.2232496","volume":"64","author":"F Locatelli","year":"2023","unstructured":"Locatelli F, Shah B, Thomas T, et al. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R\/R BCP acute lymphoblastic leukemia: a review. Leuk Lymphoma. 2023;64:1615\u201333.","journal-title":"Leuk Lymphoma"},{"key":"761_CR28","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1200\/JCO.22.02200","volume":"41","author":"LE Hogan","year":"2023","unstructured":"Hogan LE, Brown PA, Ji L, et al. Children\u2019s Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse. J Clin Oncol. 2023;41:4118\u201329. https:\/\/doi.org\/10.1200\/JCO.22.02200.","journal-title":"J Clin Oncol"},{"key":"761_CR29","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353.","journal-title":"N Engl J Med"},{"key":"761_CR30","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1182\/blood.2020007848","volume":"137","author":"E Brivio","year":"2020","unstructured":"Brivio E, Locatelli F, Lopez-Yurda M, et al. A Phase I study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2020;137:1582\u201390.","journal-title":"Blood"},{"key":"761_CR31","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","volume":"40","author":"MM O\u2019Brien","year":"2022","unstructured":"O\u2019Brien MM, Ji L, Shah NN, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40:956\u201367.","journal-title":"J Clin Oncol"},{"key":"761_CR32","unstructured":"Brivio E, Peccatori N, Ammerlaan A, et al. Inotuzumab ozogamicin in pediatric CD22-positive very high risk first relapse B-cell precursor acute lymphoblastic leukemia: preliminary results of the ITCC-059 study. Hemasphere 2025; 9. https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4160447\/erica.brivio.inotuzumab.ozogamicin.in.pediatric.cd22-positive.very.high.risk.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D3%2Asearch%3Dacute%2Blymphoblastic%2Bleukemia"},{"key":"761_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10928-018-9614-9","volume":"46","author":"M Garrett","year":"2019","unstructured":"Garrett M, Ruiz-Garcia A, Parivar K, et al. Population pharmacokinetics of inotuzumab ozogamicin in relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. J Pharmacokinet Pharmacodyn. 2019;46:211\u201322.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"761_CR34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood-2024-193946","volume":"144","author":"E Brivio","year":"2024","unstructured":"Brivio E, Pennesi E, Jang Y, et al. Sinusoidal obstruction syndrome in children with CD22+ B-cell precursors acute lymphoblastic leukemia (BCP-ALL) treated with inotuzumab ozogamicin in trial ITCC-059: risk factors and outcomes. Blood. 2024;144:310\u2013310.","journal-title":"Blood"},{"key":"761_CR35","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2021-149478","volume":"138","author":"JL McNeer","year":"2021","unstructured":"McNeer JL, O\u2019Brien MM, Rheingold SR, et al. A phase 3 randomized trial of inotuzumab ozogamicin for newly diagnosed high-risk B-ALL: safety phase results from children\u2019s oncology group protocol AALL1732. Blood. 2021;138:3398\u20133398. https:\/\/doi.org\/10.1182\/blood-2021-149478.","journal-title":"Blood"},{"key":"761_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2024023930","volume":"144","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Short NJ, Kantarjian HM, et al. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024;144:61\u201373. https:\/\/doi.org\/10.1182\/blood.2024023930.","journal-title":"Blood"},{"key":"761_CR37","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1182\/blood-2023-173907","volume":"142","author":"N Ida","year":"2023","unstructured":"Ida N, Okura M, Hosono N, et al. Combining inotuzumab ozogamicin (IO) with PARP inhibitors, olaparib and talazoparib, exerts synergistic cytotoxicity by inhibiting the repair of IO-induced DNA strand breaks in IO-resistant ALL cells. Blood. 2023;142:5804\u20135804. https:\/\/doi.org\/10.1182\/blood-2023-173907.","journal-title":"Blood"},{"key":"761_CR38","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2025-645","volume":"146","author":"M Luskin","year":"2025","unstructured":"Luskin M, Keating J, Frost B, et al. Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: results of a phase I trial. Blood. 2025;146:645\u2013645.","journal-title":"Blood"},{"key":"761_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126442","author":"A Kouhi","year":"2021","unstructured":"Kouhi A, Pachipulusu V, Kapenstein T, et al. Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22126442.","journal-title":"Int J Mol Sci"},{"key":"761_CR40","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood.2022017035","volume":"141","author":"NE Kopmar","year":"2023","unstructured":"Kopmar NE, Cassaday RD. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia. Blood. 2023;141:1379\u201388. https:\/\/doi.org\/10.1182\/blood.2022017035.","journal-title":"Blood"},{"key":"761_CR41","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2024-194244","volume":"144","author":"DJ DeAngelo","year":"2024","unstructured":"DeAngelo DJ, Chen Y, Cassaday RD, et al. Dose optimization of inotuzumab ozogamicin in adult patients with relapsed\/refractory acute lymphoblastic leukemia. Blood. 2024;144:732\u2013732.","journal-title":"Blood"},{"key":"761_CR42","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286091","author":"M \u00d6zcan","year":"2025","unstructured":"\u00d6zcan M, Cassaday RD, Zarzycka E, et al. Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study. Haematologica. 2025. https:\/\/doi.org\/10.3324\/haematol.2024.286091.","journal-title":"Haematologica"},{"key":"761_CR43","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1038\/s41375-021-01277-3","volume":"25","author":"EJ Jabbour","year":"2025","unstructured":"Jabbour EJ, Rousselot P, Gokbuget N, et al. Inotuzumab ozogamicin as first-line therapy in acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2025;25:e302\u20139. https:\/\/doi.org\/10.1038\/s41375-021-01277-3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"761_CR44","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1200\/JCO-25-01357","volume":"43","author":"H Gottschalk","year":"2025","unstructured":"Gottschalk H, M\u00f6ricke A, Conter V, et al. Reducing daunorubicin in induction therapy in children with b-lineage all with favorable prognosis: results of phase III trial AIEOP-BFM ALL 2009. J Clin Oncol. 2025;43:3739\u201349.","journal-title":"J Clin Oncol"},{"key":"761_CR45","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/JCO.2012.48.5680","volume":"31","author":"C Eckert","year":"2013","unstructured":"Eckert C, Henze G, Seeger K, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013;31:2736\u201342.","journal-title":"J Clin Oncol"},{"key":"761_CR46","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318.","journal-title":"N Engl J Med"},{"key":"761_CR47","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"761_CR48","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"761_CR49","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41:1664\u20139.","journal-title":"J Clin Oncol"},{"key":"761_CR50","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","volume":"36","author":"TW Laetsch","year":"2022","unstructured":"Laetsch TW, Maude SL, Balduzzi A, et al. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2022;36:1508\u201315.","journal-title":"Leukemia"},{"key":"761_CR51","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","volume":"9","author":"S Ghorashian","year":"2022","unstructured":"Ghorashian S, Jacoby E, De Moerloose B, et al. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. Lancet Haematol. 2022;9:e766\u201375.","journal-title":"Lancet Haematol"},{"key":"761_CR52","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","volume":"7","author":"P Bader","year":"2023","unstructured":"Bader P, Rossig C, Hutter M, et al. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany. Blood Adv. 2023;7:2436\u201348.","journal-title":"Blood Adv"},{"key":"761_CR53","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414\u201324.","journal-title":"Blood Adv"},{"key":"761_CR54","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391:2219\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2406526.","journal-title":"N Engl J Med"},{"key":"761_CR55","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502.","journal-title":"Lancet"},{"key":"761_CR56","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124.","journal-title":"Crit Care Med"},{"key":"761_CR57","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"761_CR58","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","volume":"28","author":"SJ Grant","year":"2022","unstructured":"Grant SJ, Grimshaw AA, Silberstein J, et al. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther. 2022;28:294\u2013302.","journal-title":"Transplant Cell Ther"},{"key":"761_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.634445","author":"BD Brown","year":"2021","unstructured":"Brown BD, Tambaro FP, Kohorst M, et al. Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) t-cell therapy: can we optimize early diagnosis? Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.634445.","journal-title":"Front Oncol"},{"key":"761_CR60","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15:813\u201322.","journal-title":"Expert Rev Clin Immunol"},{"key":"761_CR61","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023;29:438.e1-438.e16.","journal-title":"Transplant Cell Ther"},{"key":"761_CR62","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","volume":"57","author":"K Wudhikarn","year":"2022","unstructured":"Wudhikarn K, Perales M-A. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2022;57:1477\u201388.","journal-title":"Bone Marrow Transplant"},{"key":"761_CR63","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021012727","volume":"139","author":"AB Leahy","year":"2022","unstructured":"Leahy AB, Devine KJ, Li Y, et al. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood. 2022;139:2173\u201385.","journal-title":"Blood"},{"key":"761_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100060","volume":"2","author":"WPJ Cox","year":"2025","unstructured":"Cox WPJ, Dautzenberg NMM, Dekker L, et al. Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL. Blood Neoplasia. 2025;2:100060. https:\/\/doi.org\/10.1016\/j.bneo.2024.100060.","journal-title":"Blood Neoplasia"},{"key":"761_CR65","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","volume":"3","author":"MA Pulsipher","year":"2022","unstructured":"Pulsipher MA, Han X, Maude SL, et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov. 2022;3:66\u201381.","journal-title":"Blood Cancer Discov"},{"key":"761_CR66","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.20.03585","volume":"40","author":"LM Schultz","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40:945\u201355.","journal-title":"J Clin Oncol"},{"key":"761_CR67","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","volume":"7","author":"AJ Lamble","year":"2023","unstructured":"Lamble AJ, Myers RM, Taraseviciute A, et al. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023;7:575\u201385.","journal-title":"Blood Adv"},{"key":"761_CR68","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","volume":"40","author":"J Fischer","year":"2017","unstructured":"Fischer J, Paret C, El Malki K, et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. 2017;40:187\u201395.","journal-title":"J Immunother"},{"key":"761_CR69","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282\u201395.","journal-title":"Cancer Discov"},{"key":"761_CR70","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","volume":"139","author":"Y Qi","year":"2022","unstructured":"Qi Y, Zhao M, Hu Y, et al. Efficacy and safety of CD19-specific CAR T cell\u2013based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022;139:3376\u201386. https:\/\/doi.org\/10.1182\/blood.2021013733.","journal-title":"Blood"},{"key":"761_CR71","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1182\/blood-2025-648","volume":"146","author":"A DiNofia","year":"2025","unstructured":"DiNofia A, Myers R, Li Y, et al. CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL. Blood. 2025;146:648\u2013648. https:\/\/doi.org\/10.1182\/blood-2025-648.","journal-title":"Blood"},{"key":"761_CR72","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","volume":"2","author":"L Biasco","year":"2021","unstructured":"Biasco L, Izotova N, Rivat C, et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat Cancer Inst. 2021;2:629\u201342.","journal-title":"Nat Cancer Inst"},{"key":"761_CR73","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020023","author":"F del Bufalo","year":"2023","unstructured":"del Bufalo F, Becilli M, Rosignoli C, et al. Allogeneic, donor-derived, second-generation, CD19-CAR-T cell for the treatment of pediatric relapsed\/refractory BCP-ALL. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2023020023.","journal-title":"Blood"},{"key":"761_CR74","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","volume":"35","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wang X-Q, Zhang R-L, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35:1563\u201370.","journal-title":"Leukemia"},{"key":"761_CR75","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood-2025-646","volume":"146","author":"L Cain","year":"2025","unstructured":"Cain L, Li Y, Liu H, et al. Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia. Blood. 2025;146:646\u2013646. https:\/\/doi.org\/10.1182\/blood-2025-646.","journal-title":"Blood"},{"key":"761_CR76","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood. 2019;134:2361\u20138.","journal-title":"Blood"},{"key":"761_CR77","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","volume":"6","author":"VA Fabrizio","year":"2022","unstructured":"Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6:1961\u20138.","journal-title":"Blood Adv"},{"key":"761_CR78","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","volume":"6","author":"L Dekker","year":"2022","unstructured":"Dekker L, Calkoen FG, Jiang Y, et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 2022;6:1969\u201376.","journal-title":"Blood Adv"},{"key":"761_CR79","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/blood.2024026655","volume":"146","author":"SK Silbert","year":"2025","unstructured":"Silbert SK, Rankin AW, Hoang CN, et al. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025;146:437\u201355.","journal-title":"Blood"},{"key":"761_CR80","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah NN, Highfill SL, Shalabi H, et al. CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol. 2020;38:1938\u201350. https:\/\/doi.org\/10.1200\/JCO.19.03279.","journal-title":"J Clin Oncol"},{"key":"761_CR81","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","volume":"38","author":"LM Schultz","year":"2024","unstructured":"Schultz LM, Jeyakumar N, Kramer AM, et al. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results. Leukemia. 2024;38:963\u20138.","journal-title":"Leukemia"},{"key":"761_CR82","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood.2022015795","volume":"140","author":"H Shalabi","year":"2022","unstructured":"Shalabi H, Qin H, Su A, et al. CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood. 2022;140:451\u201363.","journal-title":"Blood"},{"key":"761_CR83","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","volume":"143","author":"S Ghorashian","year":"2024","unstructured":"Ghorashian S, Lucchini G, Richardson R, et al. CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. Blood. 2024;143:118\u201323.","journal-title":"Blood"},{"key":"761_CR84","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S Cordoba","year":"1805","unstructured":"Cordoba S, Onuoha S, Thomas S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 1805;27:1797\u2013805.","journal-title":"Nat Med"},{"key":"761_CR85","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","volume":"24","author":"J Pan","year":"2023","unstructured":"Pan J, Tang K, Luo Y, et al. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2023;24:1229\u201341.","journal-title":"Lancet Oncol"},{"key":"761_CR86","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/bloodadvances.2024012885","volume":"8","author":"RM Myers","year":"2024","unstructured":"Myers RM, Devine K, Li Y, et al. Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia. Blood Adv. 2024;8:2182\u201392.","journal-title":"Blood Adv"},{"key":"761_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.784024","author":"J Buechner","year":"2022","unstructured":"Buechner J, Caruana I, K\u00fcnkele A, et al. Chimeric antigen receptor T-cell therapy in paediatric B-cell precursor acute lymphoblastic leukaemia: curative treatment option or bridge to transplant? Front Pediatr. 2022. https:\/\/doi.org\/10.3389\/fped.2021.784024.","journal-title":"Front Pediatr"},{"key":"761_CR88","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/bloodadvances.2023011168","volume":"8","author":"M Gabelli","year":"2024","unstructured":"Gabelli M, Oporto-Espuelas M, Burridge S, et al. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy. Blood Adv. 2024;8:1959\u201363.","journal-title":"Blood Adv"},{"key":"761_CR89","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3345\/cep.2025.00031","volume":"68","author":"G Mangkuliguna","year":"2025","unstructured":"Mangkuliguna G, Tehuteru ES, Jonlean R, et al. Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed\/refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis. Clin Exp Pediatr. 2025;68:712\u201321.","journal-title":"Clin Exp Pediatr"},{"key":"761_CR90","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1182\/blood-2025-444","volume":"146","author":"M Wieduwilt","year":"2025","unstructured":"Wieduwilt M, Yin J, Kour O, et al. Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and \u2026. Blood. 2025;146:444\u2013444. https:\/\/doi.org\/10.1182\/blood-2025-444.","journal-title":"Blood"},{"key":"761_CR91","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.23.00546","volume":"42","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N, et al. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome\u2013negative B-precursor ALL. J Clin Oncol. 2024;42:273\u201382.","journal-title":"J Clin Oncol"},{"key":"761_CR92","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","volume":"12","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Lussana F, Mart\u00ednez-S\u00e1nchez P, et al. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial. Lancet Haematol. 2025;12:e529\u201341.","journal-title":"Lancet Haematol"},{"key":"761_CR93","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2025-3345","volume":"146","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Barba P, Montesinos P, et al. Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL): updated results from the phase 1\/2 SYRUS study. Blood. 2025;146:3345\u20133345. https:\/\/doi.org\/10.1182\/blood-2025-3345.","journal-title":"Blood"},{"key":"761_CR94","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2025-647","volume":"146","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yin Q, Ren J, et al. Updated results from the phase 1b\/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia. Blood. 2025;146:647\u2013647. https:\/\/doi.org\/10.1182\/blood-2025-647.","journal-title":"Blood"},{"key":"761_CR95","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2025-645","volume":"146","author":"M Luskin","year":"2025","unstructured":"Luskin M, Keating J, Frost B, et al. Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: results of a phase I trial. Blood. 2025;146:645\u2013645. https:\/\/doi.org\/10.1182\/blood-2025-645.","journal-title":"Blood"},{"key":"761_CR96","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1182\/blood-2025-1569","volume":"146","author":"Z Wan","year":"2025","unstructured":"Wan Z, Ji Y, Lou D, et al. Efficacy and safety of inotuzumab ozogamicin combined with venetoclax and dexamethasone in relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL). Blood. 2025;146:1569\u20131569. https:\/\/doi.org\/10.1182\/blood-2025-1569.","journal-title":"Blood"},{"key":"761_CR97","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/blood-2025-3352","volume":"146","author":"K Sandhu","year":"2025","unstructured":"Sandhu K, Del Real M, Macias A, et al. High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed\/refractory (r\/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1\/2 study. Blood. 2025;146:3352\u20133352. https:\/\/doi.org\/10.1182\/blood-2025-3352.","journal-title":"Blood"},{"key":"761_CR98","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2025-1562","volume":"146","author":"L Ge","year":"2025","unstructured":"Ge L, Zhou Y, Lou Y, et al. Efficacy of short-course versus standard-course blinatumomab in patients with relapsed\/refractory or MRD-positive B-cell acute lymphoblastic leukemia. Blood. 2025;146:1562\u20131562. https:\/\/doi.org\/10.1182\/blood-2025-1562.","journal-title":"Blood"},{"key":"761_CR99","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1182\/blood-2025-439","volume":"146","author":"S Chiaretti","year":"2025","unstructured":"Chiaretti S, Di Trani M, Skert C, et al. First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult Ph+ acute lymphoblastic leukemia patients. Blood. 2025;146:439\u2013439. https:\/\/doi.org\/10.1182\/blood-2025-439.","journal-title":"Blood"},{"key":"761_CR100","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e24\u201334.","journal-title":"Lancet Haematol"},{"key":"761_CR101","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2024;42:881\u20135. https:\/\/doi.org\/10.1200\/JCO.23.01075.","journal-title":"J Clin Oncol"},{"key":"761_CR102","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1182\/blood-2025-441","volume":"146","author":"A Patel","year":"2025","unstructured":"Patel A, Duvall A, Saygin C, et al. Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2025;146:441\u2013441. https:\/\/doi.org\/10.1182\/blood-2025-441.","journal-title":"Blood"},{"key":"761_CR103","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1182\/blood-2025-442","volume":"146","author":"R Gu","year":"2025","unstructured":"Gu R, Qiu S, Gong X, et al. Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: a prospective phase 2 study. Blood. 2025;146:442\u2013442. https:\/\/doi.org\/10.1182\/blood-2025-442.","journal-title":"Blood"},{"key":"761_CR104","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1182\/bloodadvances.2025016665","volume":"9","author":"M Chanut","year":"2025","unstructured":"Chanut M, Cabannes-Hamy A, Balsat M, et al. Asciminib for relapsed or refractory Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. Blood Adv. 2025;9:4580\u20134. https:\/\/doi.org\/10.1182\/bloodadvances.2025016665.","journal-title":"Blood Adv"},{"key":"761_CR105","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1182\/blood-2025-3354","volume":"146","author":"J Leonard","year":"2025","unstructured":"Leonard J, Kaempf A, Lachowiez C, et al. Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), results from a phase 1B study. Blood. 2025;146:3354\u20133354. https:\/\/doi.org\/10.1182\/blood-2025-3354.","journal-title":"Blood"},{"key":"761_CR106","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1182\/blood-2025-1582","volume":"146","author":"A Lissat","year":"2025","unstructured":"Lissat A, Bautista F, Lohi O, et al. HEM-ismart: an international proof-of-concept therapeutic stratification trial of molecular anomalies in relapsed or refractory hematological malignancies in children. Blood. 2025;146:1582.","journal-title":"Blood"},{"key":"761_CR107","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1182\/bloodadvances.2025015881","volume":"9","author":"S John","year":"2025","unstructured":"John S, Curran KJ, Hall EM, et al. Real-world data for tisagenlecleucel in patients with R\/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025;9:5249\u201362. https:\/\/doi.org\/10.1182\/bloodadvances.2025015881.","journal-title":"Blood Adv"},{"key":"761_CR108","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1182\/blood-2025-443","volume":"146","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Wang X, Zhang J, et al. CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission. Blood. 2025;146:443\u2013443. https:\/\/doi.org\/10.1182\/blood-2025-443.","journal-title":"Blood"},{"key":"761_CR109","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood-2025-516","volume":"146","author":"A Logan","year":"2025","unstructured":"Logan A, Yalniz F, Zhang A, et al. Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R\/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world. Blood. 2025;146:516\u2013516. https:\/\/doi.org\/10.1182\/blood-2025-516.","journal-title":"Blood"},{"key":"761_CR110","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/blood-2025-549","volume":"146","author":"RS Azevedo","year":"2025","unstructured":"Azevedo RS, Jabbour E, Jain N, et al. Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and\/or inotuzumab ozogamicin for relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood. 2025;146:549\u2013549. https:\/\/doi.org\/10.1182\/blood-2025-549.","journal-title":"Blood"},{"key":"761_CR111","doi-asserted-by":"publisher","first-page":"7051","DOI":"10.1200\/jco.2015.33.15_suppl.7051","volume":"33","author":"MS Topp","year":"2015","unstructured":"Topp MS, Stelljes M, Zugmaier G, et al. Re-exposure to blinatumomab after CD19-positive relapse: experience from three trials in patients (pts) with relapsed\/refractory B-precursor acute lymphoblastic leukemia (R\/R ALL). J Clin Oncol. 2015;33:7051\u20137051.","journal-title":"J Clin Oncol"},{"key":"761_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102268","author":"V Barsan","year":"2023","unstructured":"Barsan V, Li Y, Prabhu S, et al. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102268.","journal-title":"EClinicalMedicine"},{"key":"761_CR113","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1182\/blood-2023-182915","volume":"142","author":"VK Gupta","year":"2023","unstructured":"Gupta VK, Roloff GW, Muffly LS, et al. Impact of prior response to blinatumomab on outcomes of brexucabtagene autoleucel (Brexu-cel) in adult patients with relapsed or refractory (r\/r) B-cell acute lymphoblastic leukemia (B-ALL): results from the real-world outcomes collaborative of CAR-T in \u2026. Blood. 2023;142:2119\u20132119. https:\/\/doi.org\/10.1182\/blood-2023-182915.","journal-title":"Blood"},{"key":"761_CR114","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1182\/bloodadvances.2021005579","volume":"6","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Zugmaier G, Mergen N, et al. Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Adv. 2022;6:1004\u201314. https:\/\/doi.org\/10.1182\/bloodadvances.2021005579.","journal-title":"Blood Adv"},{"key":"761_CR115","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1182\/blood.2021013290","volume":"139","author":"MR Gaballa","year":"1908","unstructured":"Gaballa MR, Banerjee P, Milton DR, et al. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 1908;139:1908\u201319.","journal-title":"Blood"},{"key":"761_CR116","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s12185-022-03388-8","volume":"116","author":"H Nakayama","year":"2022","unstructured":"Nakayama H, Ogawa C, Sekimizu M, et al. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed\/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). Int J Hematol. 2022;116:612\u201321.","journal-title":"Int J Hematol"},{"key":"761_CR117","unstructured":"An updated analysis of tisagenlecleucel in pediatric\/young adult...\u2014Maude S\u2014Jun 15 2018 [cited 2026 Feb 25]. https:\/\/library.ehaweb.org\/eha\/2018\/stockholm\/214670\/shannon.maude.an.updated.analysis.of.tisagenlecleucel.in.pediatric.young.adult.html."},{"key":"761_CR118","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3324\/haematol.2022.280678","volume":"108","author":"AS Wayne","year":"2023","unstructured":"Wayne AS, Huynh V, Hijiya N, et al. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2023;108:747\u201360.","journal-title":"Haematologica"},{"key":"761_CR119","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.2025028359","volume":"146","author":"C Annesley","year":"2025","unstructured":"Annesley C, Seidel K, Wu Q, et al. Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL. Blood. 2025;146:789\u2013801. https:\/\/doi.org\/10.1182\/blood.2025028359.","journal-title":"Blood"},{"key":"761_CR120","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25:1408\u201314.","journal-title":"Nat Med"},{"key":"761_CR121","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"761_CR122","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331. https:\/\/doi.org\/10.1182\/blood-2017-08-798322.","journal-title":"Blood"},{"key":"761_CR123","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, et al. Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2016272.","journal-title":"N Engl J Med"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00761-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00761-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00761-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:06:57Z","timestamp":1790683617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00761-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":123,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00761-6","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AL has received institutional funding from AbbVie, Pfizer, Amgen, Novartis, and Astra Zeneca. CMZ has receivedinstitutional funding from Pfizer, AbbVie, Jazz, Daiichi Sankyo, Kura Oncology, and Takeda; he provides consultancy services to BeOne, Novartis, Syndax, AstraZeneca, Janssen, Incyte, Sanofi, and Taiho Oncology; and he has received speaker honorarium from Servier, BMS, and Amgen. CMZ is an Editorial Board member of Pediatric Drugs and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. EB has received institutional funding from Pfizer and Jazz; she has received speaker honorarium from Amgen. FB has received institutional funding from Pfizer, AbbVie, Jazz, Daiichi Sankyo, Kura Oncology, Takeda, and Recordatti; he provides consultancy services to BeOne. JS has received institutional funding from Amgen and Kura Oncology; she has received speaker honorarium from Amgen. FC declares that he has no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conceptualization and design of this review. EB, JS, FC, FB, and AL conducted the literature review and drafted the sections on immunotherapies in pediatric BCP-ALL. AL conducted the literature review and drafted the sections on lessons learned and future directions and FB on practical considerations. MZ drafted the section on conclusions. MZ acted as the senior author, providing critical oversight and final manuscript editing. All authors reviewed and approved the final manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}